- Home
- TRVI vs ENX Comparison
TRVI vs ENX Comparison
Compare TRVI & ENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- ENX
- Stock Information
- Founded
- TRVI 2011
- ENX 2002
- Country
- TRVI United States
- ENX United States
- Employees
- TRVI N/A
- ENX N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- ENX Finance/Investors Services
- Sector
- TRVI Health Care
- ENX Finance
- Exchange
- TRVI Nasdaq
- ENX Nasdaq
- Market Cap
- TRVI 211.4M
- ENX 175.5M
- IPO Year
- TRVI 2019
- ENX N/A
- Fundamental
- Price
- TRVI $4.51
- ENX $9.73
- Analyst Decision
- TRVI Strong Buy
- ENX
- Analyst Count
- TRVI 8
- ENX 0
- Target Price
- TRVI $9.31
- ENX N/A
- AVG Volume (30 Days)
- TRVI 4.0M
- ENX 25.4K
- Earning Date
- TRVI 11-06-2024
- ENX 01-01-0001
- Dividend Yield
- TRVI N/A
- ENX 3.94%
- EPS Growth
- TRVI N/A
- ENX N/A
- EPS
- TRVI N/A
- ENX 0.16
- Revenue
- TRVI N/A
- ENX N/A
- Revenue This Year
- TRVI N/A
- ENX N/A
- Revenue Next Year
- TRVI N/A
- ENX N/A
- P/E Ratio
- TRVI N/A
- ENX $61.00
- Revenue Growth
- TRVI N/A
- ENX N/A
- 52 Week Low
- TRVI $1.26
- ENX $7.84
- 52 Week High
- TRVI $4.60
- ENX $10.07
- Technical
- Relative Strength Index (RSI)
- TRVI 75.02
- ENX 41.04
- Support Level
- TRVI $2.36
- ENX $9.64
- Resistance Level
- TRVI $4.60
- ENX $9.89
- Average True Range (ATR)
- TRVI 0.33
- ENX 0.09
- MACD
- TRVI 0.21
- ENX -0.03
- Stochastic Oscillator
- TRVI 92.46
- ENX 16.22
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.